Ascentage Pharma announced that Prof. Xiaoyuan Gong has presented the preliminary results from a Phase II study of Ascentage Pharma’s novel drug candidate, olverembatinib, combined with reduced-intensity chemotherapy in treatment-naïve patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, in an Oral Report at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
